These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 7785970)

  • 21. Mechanism of action of rifampin on Mycobacterium smegmatis.
    White RJ; Lancini GC; Silvestri LG
    J Bacteriol; 1971 Nov; 108(2):737-41. PubMed ID: 4942761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antimycobacterial activity of a new rifamycin derivative, 3-(4-cinnamylpiperazinyl iminomethyl) rifamycin SV (T9).
    Reddy VM; Nadadhur G; Daneluzzi D; Dimova V; Gangadharam PR
    Antimicrob Agents Chemother; 1995 Oct; 39(10):2320-4. PubMed ID: 8619589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
    Dhople AM; Dimova V
    Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multivariate analysis of the activity of rifamycins against rapidly growing Mycobacteria, to define an in vitro screening model for their activity against mycobacterium leprae.
    Pattyn SR; Hébrant F
    Arzneimittelforschung; 1980; 30(12):2099-103. PubMed ID: 7011330
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic.
    Quan S; Venter H; Dabbs ER
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2456-60. PubMed ID: 9371349
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of rifampin- and ciprofloxacin-resistant Mycobacterium tuberculosis by using species-specific assays for precursor rRNA.
    Cangelosi GA; Brabant WH; Britschgi TB; Wallis CK
    Antimicrob Agents Chemother; 1996 Aug; 40(8):1790-5. PubMed ID: 8843282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Few amino acid positions in rpoB are associated with most of the rifampin resistance in Mycobacterium tuberculosis.
    Cummings MP; Segal MR
    BMC Bioinformatics; 2004 Sep; 5():137. PubMed ID: 15453919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro effect of rifampin on mycobacteria.
    Lorian V; Finland M
    Appl Microbiol; 1969 Feb; 17(2):202-7. PubMed ID: 4975656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [In vitro study on cross resistance of rifampin and rifapentine for Mycobacterium tuberculosis].
    Duanmu HJ; Liu YH; Jiang GL; Wang SM; Fu YH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):192-4. PubMed ID: 15854417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Experimental research on the organotropism at the maternal and fetal level of rifamycin SV].
    Bertè E; Moncalvo F
    G Ital Tuberc Mal Torace; 1965; 19(6):248-51. PubMed ID: 5893317
    [No Abstract]   [Full Text] [Related]  

  • 31. Growth inhibition of Mycobacterium bovis, Mycobacterium tuberculosis and Mycobacterium avium in vitro: effect of 1-beta-D-2'-arabinofuranosyl and 1-(2'-deoxy-2'-fluoro-beta-D-2'-ribofuranosyl) pyrimidine nucleoside analogs.
    Johar M; Manning T; Tse C; Desroches N; Agrawal B; Kunimoto DY; Kumar R
    J Med Chem; 2007 Jul; 50(15):3696-705. PubMed ID: 17602465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial properties of new derivatives of rifamycin SV.
    Furesz S; Arioli V; Pallanza R
    Antimicrob Agents Chemother (Bethesda); 1965; 5():770-7. PubMed ID: 4956803
    [No Abstract]   [Full Text] [Related]  

  • 33. Flavonoids as Novel Efflux Pump Inhibitors and Antimicrobials Against Both Environmental and Pathogenic Intracellular Mycobacterial Species.
    Solnier J; Martin L; Bhakta S; Bucar F
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32046221
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of concentrations of rifampin and a new rifamycin derivative, DL 473, in canine bone.
    Iversen P; Nielsen OS; Jensen KM; Madsen PO
    Antimicrob Agents Chemother; 1983 Feb; 23(2):338-40. PubMed ID: 6838192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of poxvirus maturation by rifamycin derivatives and related compounds.
    Pennington TH; Follett EA
    J Virol; 1971 Jun; 7(6):821-9. PubMed ID: 4105118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mode of action of rifampin on mycobacteria. II. Biosynthetic studies on the inhibition of ribonucleic acid polymerase of Mycobacterium bovis BCG by rifampin and uptake of rifampin- 14 C by Mycobacterium phlei.
    Konno K; Oizumi K; Oka S
    Am Rev Respir Dis; 1973 Jun; 107(6):1006-12. PubMed ID: 4576356
    [No Abstract]   [Full Text] [Related]  

  • 37. Antimycobacterial activity of rifampin under in vitro and simulated in vivo conditions.
    Stottmeier KD; Kubica GP; Woodley CL
    Appl Microbiol; 1969 Jun; 17(6):861-5. PubMed ID: 4978926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases.
    O'Brien RJ; Lyle MA; Snider DE
    Rev Infect Dis; 1987; 9(3):519-30. PubMed ID: 3037676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rifabutine: minimal inhibitory and bactericidal concentrations for Mycobacterium tuberculosis.
    Heifets LB; Lindholm-Levy PJ; Iseman MD
    Am Rev Respir Dis; 1988 Mar; 137(3):719-21. PubMed ID: 2830815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Differentiation between Mycobacterium tuberculosis and Mycobacterium bovis by means of Rifamycin SV susceptibility].
    Tsukamura M; Tsukamura S
    Igaku To Seibutsugaku; 1966 Jun; 72(6):350-2. PubMed ID: 4959327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.